BioNTech teams up with Fosun Pharma to test Covid-19 mRNA vaccine in China — and scores $50M investment

Having quietly launched its own mRNA vaccine efforts against the novel coronavirus to match the higher profile campaigns of Moderna and CureVac, Germany’s BioNTech has offered a glimpse on its progress as it unveils an alliance with a prominent Chinese player.


Ugur Sahin
Fosun Pharma will team up with BioNTech to conduct trials of its Covid-19 vaccine, BNT162, in China. To get on board, Fosun bought $50 million worth of BioNTech equity $BNTX and promised up to $85 million more in payments.

In a separate statement, BioNTech said it plans to initiate clinical testing in late April, rolling out a global development program in Europe (starting in Germany), the US and China.

資料來源: EndPoints News